VEGF antibody plus chemo shows activity in prostate Ca

PSA decline of >50% observed in three-fourths of patients, partialresponse seen in 44%

Related Content:

Drug Therapy

Oral testosterone undecanoate shows promising results for first use in the real world

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3